Publications in collaboration with researchers from Pfizer (United States) (34)

2024

  1. Effect of long-term tafamidis treatment on health-related quality of life in patients with transthyretin amyloid cardiomyopathy

    European Journal of Heart Failure, Vol. 26, Núm. 3, pp. 612-615

  2. Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer

    Clinical Drug Investigation, Vol. 44, Núm. 8, pp. 553-576

  3. Prevalence and characteristics of transthyretin amyloid cardiomyopathy in hypertrophic cardiomyopathy

    ESC Heart Failure

  4. Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study

    Revista Espanola de Cardiologia

  5. REALM-DCM: A Phase 3, Multinational, Randomized, Placebo-Controlled Trial of ARRY-371797 in Patients With Symptomatic LMNARelated Dilated Cardiomyopathy

    Circulation: Heart Failure, Vol. 17, Núm. 7, pp. e011548

  6. The effect of long-term tafamidis treatment on quality of life in people with transthyretin amyloid cardiomyopathy (ATTR-CM): A plain language summary

    Future Cardiology, Vol. 20, Núm. 11-12, pp. 595-603

2023

  1. Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations

    Journal of Thoracic Oncology, Vol. 18, Núm. 11, pp. 1581-1593

  2. Etanercept Withdrawal and Retreatment in Nonradiographic Axial Spondyloarthritis: Results of RE-EMBARK, an Open-Label Phase IV Trial

    Journal of Rheumatology, Vol. 50, Núm. 4, pp. 478-487

2022

  1. Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study

    European Journal of Cancer, Vol. 168, pp. 12-24

  2. Response to: 'Use of tanezumab for patients with hip and knee osteoarthritis with reference to a randomised clinical trial by Berenbaum and colleagues' by Riddle and Perera

    Annals of the Rheumatic Diseases

2021

  1. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  2. Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study

    European Journal of Cancer, Vol. 156, pp. 70-82

  3. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

    The Lancet Oncology, Vol. 22, Núm. 2, pp. 212-222

  4. Patient Journey in Atopic Dermatitis: The Real-World Scenario

    Dermatology and Therapy, Vol. 11, Núm. 5, pp. 1693-1705

  5. Subcutaneous tanezumab for osteoarthritis: Is the early improvement in pain and function meaningful and sustained?

    European Journal of Pain (United Kingdom), Vol. 25, Núm. 7, pp. 1525-1539

2020

  1. Cost-effectiveness analysis of second-line pharmacological treatment of acromegaly in Spain

    Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 20, Núm. 1, pp. 105-114

  2. Gaps between research and recommendations in rheumatoid arthritis

    Rheumatology International

  3. Gender differences in health-related quality of life in patients with systolic heart failure: Results of the vida multicenter study

    Journal of Clinical Medicine, Vol. 9, Núm. 9, pp. 1-15

  4. Subcutaneous tanezumab for osteoarthritis of the hip or knee: Efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period

    Annals of the Rheumatic Diseases, Vol. 79, Núm. 6, pp. 800-810

2019

  1. Development and validation of a sexual relations satisfaction scale in patients with breast cancer - "sEXSAT-Q"

    Health and Quality of Life Outcomes, Vol. 17, Núm. 1